Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position…
anno di pubblicazione 2020
-
-
TFEB-NF-κB inflammatory signaling axis: a novel therapeutic pathway of Dihydrotanshinone I in doxorubicin-induced cardiotoxicity X.…
-
Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy Maria…
-
The Science Underlying COVID-19: Implications for the Cardiovascular System Peter P Liu , Alice Blet, David Smyth , Hongliang…
-
MSK Cardio-Oncology Symposium Memorial Sloan Kettering Cancer Center 15-16 Maggio 2020, Rockefeller Research Laboratories, 430…
-
Fonte foto: http://www.YouAndLungCancer.com A Multicenter Study of Thromboembolic Events Among Patients Diagnosed With ROS1-rearranged Non-Small…
-
Doxorubicin induces cardiomyocyte apoptosis and atrophy through cyclin-dependent kinase 2-mediated activation of forkhead box O1…
-
What Cancer Patients Need to Know about Cardio-Oncology Dr. Anita Arnold, cardio-oncologist at Lee HealthClinic…
-
Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study I. Raber, S. Warack, J. Kanduri, et. al. Oncologist. 2020 Mar;25(3):e606-e609. doi: 10.1634/theoncologist.2019-0762…
-
JACC: CardioOncology March 01, 2020 | Vol. 2 No. 1 – Table of Contents of…